Goldentree Asset Management LP Sells 180,657 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Goldentree Asset Management LP lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,304,993 shares of the company’s stock after selling 180,657 shares during the quarter. Teva Pharmaceutical Industries makes up approximately 3.3% of Goldentree Asset Management LP’s holdings, making the stock its 10th largest position. Goldentree Asset Management LP owned approximately 0.20% of Teva Pharmaceutical Industries worth $41,458,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans increased its stake in shares of Teva Pharmaceutical Industries by 21.8% in the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,218 shares during the period. Coronation Fund Managers Ltd. acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $1,334,000. Pitcairn Co. bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $947,000. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after acquiring an additional 2,204,623 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of Teva Pharmaceutical Industries by 38.0% in the second quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company’s stock worth $21,437,000 after purchasing an additional 363,217 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $16.57 on Friday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The business has a fifty day simple moving average of $17.57 and a 200-day simple moving average of $17.35. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.35 and a fifty-two week high of $19.31.

Wall Street Analysts Forecast Growth

TEVA has been the topic of several research analyst reports. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, UBS Group lifted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.